What happened with BEAT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
HeartBeam helps physicians assess abnormal heart rhythms outside the clinic. Its HeartBeam System uses a credit-card-sized, cable-free device to record the heart’s electrical activity, then converts those recordings into a 12-lead electrocardiogram (ECG). A patient app, physician portal and cloud software connect the readings with care, including on-demand review by a board-certified cardiologist.
The company is beginning commercialization after reporting no revenue in 2025. It named preventive cardiology practice ClearCardio as its first commercial customer under a letter of intent that includes a per-patient subscription fee and a staged rollout; a definitive agreement remains to be negotiated. HeartBeam initially targets U.S. practices where device payment falls outside established insurance reimbursement, with broader insurance coverage a longer-term goal. Sales depend on physicians prescribing and using the system. FDA clearance covers arrhythmia assessment; heart-attack detection remains a planned future use requiring further regulatory clearance.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
HeartBeam’s results hinge on commercial adoption of its newly cleared ECG system, including the planned ClearCardio rollout, against alternatives such as AliveCor’s KardiaMobile and SHL Telemedicine’s Smartheart.
iRhythm Holdings, Inc.’s Zio patches compete with HeartBeam’s portable ECG system as ways for physicians to detect arrhythmias outside the clinic. iRhythm earns revenue from physician-ordered monitoring services that continuously record ECGs for up to 14 days, making demand for those services a useful sign of the alternative HeartBeam must compete against.
Boston Scientific’s BodyGuardian competes with HeartBeam’s portable ECG system for physician-directed arrhythmia monitoring outside the clinic, but monitoring is only one part of its broad medical-device business. For HeartBeam investors, BodyGuardian news is more directly relevant than Boston Scientific’s overall results, which also reflect devices used across many other medical specialties.
iRhythm Holdings, Inc. earningsIRTC
iRhythm's report will show whether physicians are still ordering its Zio monitoring services, an established alternative to HeartBeam's system for detecting arrhythmias outside the clinic.
Watch whether iRhythm's revenue from physician-ordered monitoring services is growing. Growth would show physicians continue to use this kind of out-of-clinic arrhythmia monitoring, making it harder for HeartBeam to win the same work. Slowing or falling revenue would point to weaker momentum for this alternative, but would not show that physicians will switch to HeartBeam.
Heartbeam, Inc. earningsThis company
This report will show whether HeartBeam's planned ClearCardio rollout is beginning to bring in sales, and how much the company is still spending to develop and launch its system.
Read sales alongside cash use. Sales beginning while available cash and financing support ongoing development and launch would show a commercial foothold, not profitability. Little or no sales while cash continues to be used would mean sales have not eased the funding need; HeartBeam may need outside financing, and issuing shares could reduce existing holders' ownership percentages.
